Integra LifeSciences Holdings (IART)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	67,741	100,853	131,271	171,875	180,550	172,988	166,302	156,582	169,075	216,435	205,543	170,106	133,892	56,467	-3,480	26,625	50,201	60,020	100,925	82,565
Total stockholders’ equity	US$ in thousands	1,587,880	1,579,220	1,683,160	1,674,940	1,804,400	1,724,410	1,660,920	1,615,200	1,684,800	1,631,690	1,574,980	1,529,330	1,514,870	1,397,990	1,349,100	1,341,800	1,416,740	1,384,970	1,420,950	1,397,030
ROE		4.27%	6.39%	7.80%	10.26%	10.01%	10.03%	10.01%	9.69%	10.04%	13.26%	13.05%	11.12%	8.84%	4.04%	-0.26%	1.98%	3.54%	4.33%	7.10%	5.91%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $67,741K ÷ $1,587,880K
= 4.27%

Integra Lifesciences Holdings Corp's return on equity (ROE) has shown some variability in recent quarters. The ROE for the company ranged from a low of 4.27% in Q4 2023 to a high of 10.26% in Q1 2023. This indicates fluctuations in the company's profitability and efficiency in generating returns for its shareholders during these periods. Overall, the ROE trend suggests that the company has experienced some challenges in consistently maximizing shareholder value, with performance dipping in the most recent quarter. Analyzing the underlying factors influencing these fluctuations could provide insights into the company's financial health and strategic direction.